Latest Insider Transactions at Vyne Therapeutics Inc. (VYNE)
This section provides a real-time view of insider transactions for Vyne Therapeutics Inc. (VYNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VYNE Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VYNE Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2022
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,813
-0.78%
|
$0
$0.22 P/Share
|
|
Sep 30
2022
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,683
-1.02%
|
$0
$0.22 P/Share
|
|
Jun 30
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-0.2%
|
$0
$0.39 P/Share
|
|
Jun 30
2022
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-0.76%
|
$0
$0.39 P/Share
|
|
Jun 30
2022
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,813
-0.77%
|
$0
$0.39 P/Share
|
|
Jun 30
2022
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,683
-1.01%
|
$0
$0.39 P/Share
|
|
May 31
2022
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,887
+1.11%
|
$0
$0.35 P/Share
|
|
May 31
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,510
+6.71%
|
$0
$0.35 P/Share
|
|
Mar 31
2022
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,186
-2.16%
|
$0
$0.65 P/Share
|
|
Mar 31
2022
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
3,630
-1.52%
|
$0
$0.65 P/Share
|
|
Mar 31
2022
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,469
-1.52%
|
$0
$0.65 P/Share
|
|
Mar 31
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
773
-0.48%
|
$0
$0.65 P/Share
|
|
Mar 17
2022
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
312,302
+22.55%
|
-
|
|
Mar 17
2022
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+23.95%
|
-
|
|
Mar 17
2022
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+24.68%
|
-
|
|
Mar 17
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+31.6%
|
-
|
|
Dec 31
2021
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,887
-0.9%
|
$6,887
$1.02 P/Share
|
|
Dec 31
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-0.9%
|
$1,484
$1.02 P/Share
|
|
Dec 31
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,250
-0.81%
|
$1,250
$1.02 P/Share
|
|
Dec 31
2021
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.24%
|
$206
$1.02 P/Share
|
|
Nov 30
2021
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,705
+0.61%
|
$0
$0.88 P/Share
|
|
Nov 30
2021
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
12,500
+16.67%
|
$12,500
$1.02 P/Share
|
|
Nov 30
2021
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,187
+4.56%
|
$0
$0.88 P/Share
|
|
Sep 30
2021
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,096
-1.69%
|
$13,096
$1.39 P/Share
|
|
Sep 30
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-0.89%
|
$1,484
$1.39 P/Share
|
|
Sep 30
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,480
-0.95%
|
$1,480
$1.39 P/Share
|
|
Sep 30
2021
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.25%
|
$206
$1.39 P/Share
|
|
Sep 02
2021
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
320,312
+29.22%
|
-
|
|
Sep 02
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
60,859
+26.81%
|
-
|
|
Sep 02
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,859
+27.99%
|
-
|
|
Sep 02
2021
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,859
+42.14%
|
-
|
|
Aug 25
2021
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
12,500
+20.0%
|
$12,500
$1.6 P/Share
|
|
Aug 16
2021
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
250,000
-4.82%
|
$250,000
$1.74 P/Share
|
|
Aug 13
2021
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
250,000
-4.6%
|
$250,000
$1.84 P/Share
|
|
Aug 12
2021
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
338,897
-5.87%
|
$677,794
$2.23 P/Share
|
|
Jun 30
2021
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,859
-3.97%
|
$56,577
$3.51 P/Share
|
|
Jun 30
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
3,551
-3.26%
|
$10,653
$3.51 P/Share
|
|
Jun 30
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,083
-3.12%
|
$9,249
$3.51 P/Share
|
|
Jun 30
2021
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,151
-4.5%
|
$15,453
$3.51 P/Share
|
|
Jun 30
2021
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
700
-2.99%
|
$2,100
$3.51 P/Share
|
|
May 28
2021
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
941
+0.2%
|
$2,823
$3.36 P/Share
|
|
May 28
2021
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,017
+2.53%
|
$9,051
$3.36 P/Share
|
|
May 26
2021
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
12,500
+25.0%
|
$37,500
$3.6 P/Share
|
|
May 06
2021
|
Perceptive Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,000
-14.76%
|
$3,000,000
$3.67 P/Share
|
|
Mar 31
2021
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,316
-1.32%
|
$37,896
$6.84 P/Share
|
|
Mar 31
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,765
-1.6%
|
$10,590
$6.84 P/Share
|
|
Mar 31
2021
|
Andrew Saik Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
762
-0.67%
|
$4,572
$6.84 P/Share
|
|
Mar 31
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-1.93%
|
$11,670
$6.84 P/Share
|
|
Mar 31
2021
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,573
-2.2%
|
$15,438
$6.84 P/Share
|
|
Mar 15
2021
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
12,500
+33.33%
|
$87,500
$7.41 P/Share
|